Endostatin

Generic Name
Endostatin
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
187888-07-9
Unique Ingredient Identifier
67RHC0R671
Indication

Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Local Injection and Systemic Therapy in the Treatment of NSCLC.

First Posted Date
2024-09-30
Last Posted Date
2024-09-30
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
84
Registration Number
NCT06618391

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

First Posted Date
2023-09-21
Last Posted Date
2023-09-21
Lead Sponsor
Second Affiliated Hospital of Soochow University
Target Recruit Count
30
Registration Number
NCT06047860
Locations
🇨🇳

The Second Affiliated Hospital of SchoowUniversity, Suzhou, China

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

First Posted Date
2022-07-07
Last Posted Date
2022-07-07
Lead Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Target Recruit Count
38
Registration Number
NCT05448781
Locations
🇨🇳

Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China

Modified CV Regimen in Optic Pathway Glioma

First Posted Date
2022-03-14
Last Posted Date
2024-10-11
Lead Sponsor
Beijing Sanbo Brain Hospital
Target Recruit Count
75
Registration Number
NCT05278715
Locations
🇨🇳

Capital Medical University Sanbo Brain Hospital, Beijing, China

Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

First Posted Date
2020-04-22
Last Posted Date
2020-05-27
Lead Sponsor
Hui Bu
Target Recruit Count
30
Registration Number
NCT04356118

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Phase 2
Conditions
Staging IV NSCLC
Interventions
Drug: Rh-endostatin
First Posted Date
2019-09-19
Last Posted Date
2020-02-07
Lead Sponsor
Guangzhou Institute of Respiratory Disease
Target Recruit Count
186
Registration Number
NCT04094909
Locations
🇨🇳

Zhou Chengzhi, Guangzhou, Guangdong, China

Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors

First Posted Date
2019-06-18
Last Posted Date
2020-10-23
Lead Sponsor
Sun Yan
Target Recruit Count
53
Registration Number
NCT03989830
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Breast Cancer Treatment Based on Organ-like Culture

First Posted Date
2019-04-24
Last Posted Date
2019-04-24
Lead Sponsor
Xijing Hospital
Target Recruit Count
300
Registration Number
NCT03925233
Locations
🇨🇳

JingSu, Xi'an, Shaanxi, China

Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)

First Posted Date
2017-07-05
Last Posted Date
2017-07-05
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
61
Registration Number
NCT03208335
Locations
🇨🇳

Chinese PLA Gereral Hospital, Beijing, Beijing, China

Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma

Phase 2
Conditions
Melanoma
Interventions
Drug: recombinant human endostatin
First Posted Date
2017-03-29
Last Posted Date
2017-03-29
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
70
Registration Number
NCT03095079
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy